Spyre Therapeutics, Inc. (SYRE)
43.00
-0.15
(-0.35%)
USD |
NASDAQ |
Feb 27, 16:00
43.00
0.00 (0.00%)
After-Hours: 20:00
Spyre Therapeutics Research and Development Expense (Quarterly) : 44.64M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| PTC Therapeutics, Inc. | 133.13M |
| Tandem Diabetes Care, Inc. | 46.07M |
| ACADIA Pharmaceuticals, Inc. | 84.76M |
| Alnylam Pharmaceuticals, Inc. | 372.22M |
| Savara, Inc. | 20.59M |